ER+/HER2- advanced or metastatic breast cancer
Clinical trials for ER+/HER2- advanced or metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new ER+/HER2- advanced or metastatic breast cancer trials appear
Sign up with your email to follow new studies for ER+/HER2- advanced or metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new pill outsmart resistant breast cancer?
Disease control Recruiting nowThis trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…
Matched conditions: ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Phase 2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a Two-Drug combo outsmart resistant breast cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…
Matched conditions: ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC